Skip to Content

ARK Genomic Revolution fund starts position in Burning Rock Biotech

The ARK Genomic Revolution ETF (ARKG) started a position in Burning Rock Biotech (BNR), a Chinese cancer sequencing technology company that jumped 11% after reporting third-quarter results. The loss-making biotech saw its revenue edge up 2% in the third quarter and is planning two products for early-stage cancer patients next year. In other moves, two Ark funds sold nearly $23 million worth of Unity Software (U), while the ARK Next Generation Internet ETF continued to boost its holding in Robinhood Markets (HOOD).

-Steve Goldstein


(END) Dow Jones Newswires

11-17-21 0357ET

Copyright (c) 2021 Dow Jones & Company, Inc.